From Schedule I to the Clinic—Insights Into Psychedelic Drug Development From GHB
Brian S. Barnett, Franklin King
JAMA Psychiatry July 15, 2026 DOI: 10.1001/jamapsychiatry.2026.1901 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The regulatory pathway used for sodium oxybate may serve as a model for other Schedule I substances, including psychedelics. |
Abstract
This Viewpoint reviews the case of sodium oxybate, a product of gamma-hydroxybutyrate (GHB), to illustrate how psychedelics and other Schedule I substances can proceed through a similar regulatory pathway.